HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Disopyramide (Norpace)

Subscribe to New Research on Disopyramide

A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.

Also Known As:

Norpace; Diisopyramide; Disopyramide Monohydrochloride; Disopyramide Phosphate; Disopyramide Phosphate (1:1); Disopyramide Phosphate (1:1), (+-)-Isomer; Disopyramide Phosphate (1:1), (R)-Isomer; Disopyramide Phosphate (1:1), (S)-Isomer; Disopyramide, (+-)-Isomer; Disopyramide, (R)-Isomer; Disopyramide, (S)-Isomer; Disopyramide, D-Tartrate (1:1), (S)-Isomer; Disopyramide, L-Tartrate (1:1), (R)-Isomer; Disopyramide, L-Tartrate (1:1), (S)-Isomer; Disopyramide, L-Tartrate (1:2), (+-)-Isomer; Disopyramide, L-Tartrate, (S)-isomer; Palpitin; Palpitine; Rhythmodan; Ritmilen; Rythmilen; SC-13957; Monohydrochloride, Disopyramide; Phosphate, Disopyramide; SC 13957; SC13957; 2-Pyridineacetamide, alpha-(2-(bis(1-methylethyl)amino)ethyl)-alpha-phenyl-

Networked: 593 relevant articles (78 outcomes, 71 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 1-Ring Heterocyclic Compounds
  - Pyridines: 41
    - Disopyramide: 593
      - isopropyl disopyramide: 1
      - 4-(isopropylamino)-2-(2-pyridyl)-2-phenylbutyramide

Experts

1.	Minami, Yuichiro: 4 articles (09/2015 - 01/2010)
2.	Sherrid, Mark V: 4 articles (05/2012 - 04/2005)
3.	Hagiwara, Nobuhisa: 3 articles (09/2015 - 01/2010)
4.	Lafuente-Lafuente, Carmelo: 3 articles (01/2015 - 04/2006)
5.	Bergmann, Jean-François: 3 articles (01/2015 - 04/2006)
6.	Kajimoto, Katsuya: 3 articles (11/2010 - 01/2010)
7.	Komatsu, Takashi: 3 articles (09/2010 - 04/2003)
8.	Haruki, Shintaro: 2 articles (09/2015 - 01/2010)
9.	Belmin, Joël: 2 articles (01/2015 - 01/2012)
10.	Kawana, Masatoshi: 2 articles (05/2010 - 01/2010)

Related Diseases

1.	Atrial Fibrillation 07/01/1985 - "When used for removal of atrial fibrillation paroxysms ritmilen is effective in doses of 1.2-1.7 mg/kg intravenously and in doses of 2.5-3.8 mg/kg per os. " 05/01/1999 - "The purpose of this present study was to test whether P-SAECG mapping system would give any information on the efficacy of disopyramide on the prevention of paroxysmal atrial fibrillation (PAF). " 09/01/2003 - "The efficacy of disopyramide in preventing the recurrence of atrial fibrillation varies with the duration of the previous episode. " 05/01/1999 - "Dispersion of filtered P wave duration by P wave signal-averaged ECG mapping system: its usefulness for determining efficacy of disopyramide on paroxysmal atrial fibrillation." 01/01/1991 - "Efficacy of disopyramide in conversion and prophylaxis of post-thyrotoxic atrial fibrillation."
2.	Cardiac Arrhythmias (Arrythmia) 01/01/1990 - "The effectiveness of Palpitin was expressed as improvement in 66% of cases (reduction of ectopic beats by 75%), and in 40% of cases complete regression of arrhythmia was achieved. " 05/01/1984 - "The dosage regimen of intravenous disopyramide evaluated was effective in 60% of patients with ventricular arrhythmia, induced no severe toxic effects, and rapidly achieved therapeutic serum levels that were maintained during continuous infusion." 05/01/1977 - "Intravenous therapy with disopyramide in the dosage regimen employed appears to be moderately effective against supraventricular arrhythmia and particularly effective against ventricular arrhythmia with minimal toxicity. " 01/01/1981 - "Efficacy of intravenous disopyramide in acute cardiac arrhythmias." 12/01/1980 - "[Clinical efficacy of disopyramide in the treatment of cardiac arrhythmias (author's transl)]."
3.	Tachycardia (Tachyarrhythmias) 08/01/1982 - "Oral disopyramide phosphate is effective in preventing induction of sustained AV reentrant tachycardia in most patients. " 02/01/1985 - "Disopyramide is effective in the treatment of post-operative atrial tachyarrhythmias, but its routine use in this situation may be associated with an unacceptably high incidence of side-effects." 01/01/1984 - "In these 4 patients, oral disopyramide was also effective in preventing spontaneous occurrence of tachycardia. " 06/01/1977 - "Therefore, these data document the therapeutic efficacy of disopyramide in the treatment of refractory life-threatening ventricular tachyarrhythmias." 04/01/1986 - "In this study, the safety and efficacy of long-term therapy with disopyramide phosphate were evaluated in 40 patients with documented, recurrent, symptomatic tachyarrhythmias. "
4.	Ventricular Tachycardia 06/01/1977 - "Intravenous administration of disopyramide resulted in more effective electrical stability in all patients and completely eliminated ventricular tachycardia in six. " 05/01/1984 - "The purpose of our study was to assess the efficacy of Propafenon in comparison with Disopyramide in the long-term treatment of repetitive ventricular tachycardia. " 06/01/1977 - "Efficacy of disopyramide phosphate in the treatment of refractory ventricular tachycardia." 02/01/1981 - "[Induction and termination of ventricular tachycardia by programmed electrical stimulation of heart--a case in which the effect of disopyramide phosphate was confirmed by the stimulation study (author's transl)]." 10/01/1995 - "One patient had a recurrence of a well tolerated ventricular tachycardia on disopyramide. "
5.	Ventricular Premature Complexes (Premature Ventricular Contraction) 06/01/1989 - "Ritmilen is highly effective in ventricular extrasystole in the presence of slow sinus rhythm." 01/01/1986 - "Disopyramide gave a marked and significant reduction of ventricular ectopic beats both at rest and during and after exercise. " 12/01/1985 - "Low-dose (7 mg/kg per day) disopyramide administration to arrhythmic chagasic patients decreased the frequency of ventricular extrasystoles in 4 of 17 patients (24%) and suppressed most complex ventricular arrhythmias in 12 of 15 patients (80%). " 10/01/1984 - "i. d.) compared to disopyramide (D) (200 mg t.i.d.) was thus investigated using a double-blind crossover placebo-controlled protocol in 12 patients, aged 13 to 67 years, with chronic stable high frequency premature ventricular beats (PVB), defined as greater than 100 PVB/h during 48-72-h control Holter monitoring. " 09/01/1983 - "We tested the safety of multiple bolus loading for intravenous disopyramide in 10 patients with frequent premature ventricular beats. "

Related Drugs and Biologics

1.	Quinidine (Chinidin)
2.	Propafenone (Rythmol)
3.	Verapamil (Calan)
4.	Lidocaine (Xylocaine)
5.	Amiodarone (Amiodarona)
6.	Mexiletine (Mexitil)
7.	Procainamide (Procan)
8.	Flecainide (Tambocor)
9.	Anti-Arrhythmia Agents
10.	Moricizine (Moracizine)

Related Therapies and Procedures

1.	Oral Administration
2.	Electric Countershock (Cardioversion)
3.	Intravenous Infusions
4.	Ligation
5.	Drug Therapy (Chemotherapy)